In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...

London-listed PRTech firm Pathos Communications has built a proprietary AI platform, PathosMind, for internal use by its employees and partners. The system is designed to identify stories that ...

Developed by London Stock Exchange–listed MediaTech firm Pathos Communications, PathosMind is a proprietary AI platform designed to surface stories that truly resonate with audiences. By scanning more ...

Founded in 2019, Pathos was ranked as the fastest growing advertising and marketing company in the UK in the Financial Times 1000, and the 33rd fastest growing company in Europe in the same ranking.

(Alliance News) - Pathos Communications PLC on Wednesday said it expects a market capitalisation of GBP20.0 million on admission to London's AIM, as it confirmed the expected admission date is on ...

A British marketing agency ranked among Europe's fastest-growing businesses is planning to float on the London Stock Exchange later this month, The Mail on Sunday understands. Pathos Communications, ...

TBC - website address containing all information required by AIM Rule 26 will be confirmed in due course and be made live on admission Pathos is a technology-enabled ...

Increased global competition has fuelled disruption and competition in almost all industries. There are notable exceptions, however, where businesses are not spoilt for choice. One of those is in the ...

Why you can trust What Hi-Fi? Our expert team reviews products in dedicated test rooms, to help you make the best choice for your budget. Find out more about how we test. Pathos’s Inpol Remix MkII is ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In the latest edition of The ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...